{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:19:48Z","timestamp":1794557988428,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["ME4050\/12-1"],"award-info":[{"award-number":["ME4050\/12-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["MzH3\/020\/20"],"award-info":[{"award-number":["MzH3\/020\/20"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["Lipid Immune Neuropathy Consortium"],"award-info":[{"award-number":["Lipid Immune Neuropathy Consortium"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common and potentially life-threatening complication of chimeric antigen receptor (CAR) T cell therapy. The underlying mechanisms of ICANS remain incompletely understood and are unlikely to be explained by cytokine excess alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed paired peripheral blood and cerebrospinal fluid (CSF) samples from CAR T cell\u2013treated patients who developed ICANS (<jats:italic>n<\/jats:italic>\u2009=\u200911) within 5\u201321 days post-infusion. ICANS severity was graded as follows: grade 1 (<jats:italic>n<\/jats:italic>\u2009=\u20093), grade 2 (<jats:italic>n<\/jats:italic>\u2009=\u20094), grade 3 (<jats:italic>n<\/jats:italic>\u2009=\u20091), and grade 4 (<jats:italic>n<\/jats:italic>\u2009=\u20093). Control samples were obtained from patients with idiopathic intracranial hypertension, functional neurological disorders, and multiple sclerosis. We employed single-cell RNA sequencing (scRNA-seq) and flow cytometry to profile immune cell populations and performed multi-modal spatial transcriptomics and immunofluorescence on postmortem choroid plexus and brain tissue from a patient with fatal grade 4 ICANS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified a distinct population of proliferating, cytotoxic T cells characterized by CXCR6 expression, enriched in CD4\u2009+\u2009CAR T cells and predominantly localized in ICANS CSF. These CXCR6\u2009+\u2009T cells were largely absent from control CSF samples. Spatial mapping of postmortem brain tissue revealed widespread infiltration of myeloid cells and a striking spatial association between CXCR6\u2009+\u2009T cells and CXCL16-expressing myeloid cells in both the choroid plexus and brain parenchyma. Notably, CSF levels of CXCL16 positively correlated with ICANS severity across the cohort, from grade 1 to grade 4.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings implicate the CXCL16\/CXCR6 axis in the recruitment of cytotoxic CAR CD4\u2009+\u2009T cells to the central nervous system (CNS) during ICANS. This interaction may be linked to neuroinflammatory processes and severity stratification in ICANS pathogenesis. These results provide a mechanistic rationale for exploring CXCL16\/CXCR6 as a potential biomarker and therapeutic target in CAR T cell-associated neurotoxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13073-025-01498-6","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:04:31Z","timestamp":1751277871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The CXCL16\/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy"],"prefix":"10.1186","volume":"17","author":[{"given":"I-Na","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"M\u00fcller-Miny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Krekeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis Fung-Yi","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Antonopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Jeibmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schulte-Mecklenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelius","family":"Kerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalen","family":"Bleckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Meyer zu H\u00f6rste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver M.","family":"Grauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"1498_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"1498_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396.","journal-title":"Nat Rev Immunol"},{"key":"1498_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1498_CR4","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"1498_CR5","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:3010\u201320.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1498_CR6","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319.","journal-title":"Cancer Discov"},{"key":"1498_CR7","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1709866. Cited 2024 Jun 2."},{"key":"1498_CR8","doi-asserted-by":"crossref","unstructured":"Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4:3123\u20137. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/3123\/461283\/Clinical-efficacy-of-anakinra-to-mitigate-CAR\u00a0. Cited 2024 Jun 2.","DOI":"10.1182\/bloodadvances.2020002328"},{"key":"1498_CR9","doi-asserted-by":"crossref","unstructured":"Chen L-Y, Kang L-Q, Zhou H-X, Gao H-Q, Zhu X-F, Xu N, et al. Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. Transl Oncol. 2020;13:100838. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320303302. Cited 2024 Jun 2.\u00a0","DOI":"10.1016\/j.tranon.2020.100838"},{"key":"1498_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019;86:42\u201354.","journal-title":"Ann Neurol"},{"key":"1498_CR11","doi-asserted-by":"crossref","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/8\/958\/10154\/Clinical-and-Biological-Correlates-of. Cited 2024 Jun 2.","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"1498_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348.","journal-title":"Nat Med"},{"key":"1498_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183:126-142.e17.","journal-title":"Cell"},{"key":"1498_CR14","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099\u2013103.","journal-title":"Nat Med"},{"key":"1498_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23:943\u20137.","journal-title":"Oncologist"},{"key":"1498_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8: e001511.","journal-title":"J Immunother Cancer"},{"key":"1498_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","volume":"81","author":"DI Friedman","year":"2013","unstructured":"Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81:1159\u201365.","journal-title":"Neurology"},{"key":"1498_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"1498_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o64","volume":"376","author":"S Aybek","year":"2022","unstructured":"Aybek S, Perez DL. Diagnosis and management of functional neurological disorder. BMJ. 2022;376: o64.","journal-title":"BMJ"},{"key":"1498_CR20","doi-asserted-by":"crossref","unstructured":"Hallett M, Aybek S, Dworetzky BA, McWhirter L, Staab JP, Stone J. Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol. 2022;21:537\u201350. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1474442221004221\u00a0. Cited 2025 Jun 11.","DOI":"10.1016\/S1474-4422(21)00422-1"},{"key":"1498_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"1498_CR22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"1498_CR23","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:3978\u201392.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1498_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"1498_CR25","doi-asserted-by":"crossref","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259\u201375. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421048766. Cited 2024 Aug 17.","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"1498_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100533","volume":"3","author":"H Touil","year":"2023","unstructured":"Touil H, Roostaei T, Calini D, Diaconu C, Epstein S, Raposo C, et al. A structured evaluation of cryopreservation in generating single-cell transcriptomes from cerebrospinal fluid. Cell Rep Methods. 2023;3: 100533.","journal-title":"Cell Rep Methods"},{"key":"1498_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12974-024-03047-1","volume":"21","author":"MC Kodali","year":"2024","unstructured":"Kodali MC, Antone J, Alsop E, Jayakumar R, Parikh K, Chiot A, et al. Cryopreservation of cerebrospinal fluid cells preserves the transcriptional landscape for single-cell analysis. J Neuroinflammation. 2024;21:71.","journal-title":"J Neuroinflammation"},{"key":"1498_CR28","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28:1848\u201359.","journal-title":"Nat Med"},{"issue":"32","key":"1498_CR29","first-page":"689","volume":"2009","author":"JN Kochenderfer","year":"1997","unstructured":"Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother Hagerstown Md. 1997;2009(32):689\u2013702.","journal-title":"J Immunother Hagerstown Md"},{"key":"1498_CR30","unstructured":"Hao Y, Stuart T, Kowalski M, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal, and scalable single-cell analysis . Genomics. 2022. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.02.24.481684.\u00a0Posted 26 Feb 2022."},{"key":"1498_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13059-019-1865-2","volume":"20","author":"Y Huang","year":"2019","unstructured":"Huang Y, McCarthy DJ, Stegle O. Vireo: Bayesian demultiplexing of pooled single-cell RNA-seq data without genotype reference. Genome Biol. 2019;20:273.","journal-title":"Genome Biol"},{"key":"1498_CR32","doi-asserted-by":"publisher","first-page":"giaa151","DOI":"10.1093\/gigascience\/giaa151","volume":"9","author":"MD Young","year":"2020","unstructured":"Young MD, Behjati S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. GigaScience. 2020;9:giaa151.","journal-title":"GigaScience."},{"key":"1498_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13059-021-02584-9","volume":"23","author":"S Choudhary","year":"2022","unstructured":"Choudhary S, Satija R. Comparison and evaluation of statistical error models for scRNA-seq. Genome Biol. 2022;23:27.","journal-title":"Genome Biol"},{"key":"1498_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16:1289\u201396.","journal-title":"Nat Methods"},{"key":"1498_CR35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, et al. Inference and analysis of cell-cell communication using Cell Chat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"1498_CR36","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1093\/bioinformatics\/btac582","volume":"38","author":"B Phipson","year":"2022","unstructured":"Phipson B, Sim CB, Porrello ER, Hewitt AW, Powell J, Oshlack A. propeller: testing for differences in cell type proportions in single cell data. Bioinforma Oxf Engl. 2022;38:4720\u20136.","journal-title":"Bioinforma Oxf Engl"},{"key":"1498_CR37","doi-asserted-by":"publisher","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang Z, Liu X, Peltz G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinforma Oxf Engl. 2023;39:btac757.","journal-title":"Bioinforma Oxf Engl."},{"key":"1498_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding N, Bormann NL, Kraus G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Research. 2020;9:47.","journal-title":"F1000Research."},{"key":"1498_CR39","doi-asserted-by":"crossref","unstructured":"Vadim I. Nazarov and Vasily O. Tsvetkov and Siarhei Fiadziushchanka and Eugene Rumynskiy and Aleksandr A. Popov and Ivan Balashov and Maria Samokhina. immunarch: Bioinformatics Analysis of T-Cell and B-Cell Immune Repertoires. 2023. Available from: https:\/\/immunarch.com\/, https:\/\/github.com\/immunomind\/immunarch.\u00a0Posted 15 Aug 2019.","DOI":"10.32614\/CRAN.package.immunarch"},{"key":"1498_CR40","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1038\/s41467-024-48195-3","volume":"15","author":"I-N Lu","year":"2024","unstructured":"Lu I-N, Cheung PF-Y, Heming M, Thomas C, Giglio G, Leo M, et al. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment. Nat Commun. 2024;15:4120.","journal-title":"Nat Commun."},{"key":"1498_CR41","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/glia.23575","volume":"67","author":"AK Shukla","year":"2019","unstructured":"Shukla AK, McIntyre LL, Marsh SE, Schneider CA, Hoover EM, Walsh CM, et al. CD11a expression distinguishes infiltrating myeloid cells from plaque-associated microglia in Alzheimer\u2019s disease. Glia. 2019;67:844\u201356.","journal-title":"Glia"},{"key":"1498_CR42","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.immuni.2023.11.011","volume":"56","author":"CM Wilk","year":"2023","unstructured":"Wilk CM, Cathomas F, T\u00f6r\u00f6k O, Le Berichel J, Park MD, Bigenwald C, et al. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023;56:2790-2802.e6.","journal-title":"Immunity"},{"key":"1498_CR43","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.celrep.2016.10.052","volume":"17","author":"RL Bowman","year":"2016","unstructured":"Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 2016;17:2445\u201359.","journal-title":"Cell Rep"},{"key":"1498_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1742-2094-7-9","volume":"7","author":"S Alboni","year":"2010","unstructured":"Alboni S, Cervia D, Sugama S, Conti B. Interleukin 18 in the CNS. J Neuroinflammation. 2010;7:9.","journal-title":"J Neuroinflammation"},{"key":"1498_CR45","doi-asserted-by":"crossref","unstructured":"Aguilera-Dur\u00e1n G, Romo-Mancillas A. Behavior of chemokine receptor 6 (CXCR6) in complex with CXCL16 soluble form chemokine by molecular dynamic simulations: general protein\u2012ligand interaction model and 3D-QSAR studies of synthetic antagonists. Life. 2021;11:346. Available from: https:\/\/www.mdpi.com\/2075-1729\/11\/4\/346. Cited 2025 Feb 11.","DOI":"10.3390\/life11040346"},{"key":"1498_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126899","volume":"30","author":"S Peddibhotla","year":"2020","unstructured":"Peddibhotla S, Hershberger PM, Jason Kirby R, Sugarman E, Maloney PR, Hampton Sessions E, et al. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma. Bioorg Med Chem Lett. 2020;30: 126899.","journal-title":"Bioorg Med Chem Lett"},{"key":"1498_CR47","doi-asserted-by":"crossref","unstructured":"Lu I-N, M\u00fcller-Miny L, Meyer zu Horste G, Grauer OM. The CXCL16\/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Gene Expression Omnibus. 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?&acc=GSE269379.\u00a0Accessed 12 May 2025.","DOI":"10.1186\/s13073-025-01498-6"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01498-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T23:59:07Z","timestamp":1757203147000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-025-01498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01498-6","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the author name metadata.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each patient prior to enrollment, following approval from the Ethics Committee of the Board of Physicians of the Region Westfalen-Lippe and the University of M\u00fcnster (reference: 2010-262-f-S,\u00a02015\u2013522-f-S, 2021\u2013198-f-S, 2024\u2013345-f-S). Clinical data and CSF samples were collected in accordance with ethical guidelines and the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"INL, LMM, GMzH, and OG have filed a patent application concerning the diagnostic and therapeutic use of the CXCL16-CXCR6 axis in ICANS. The remaining authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}